Document is current
Any future updates will be listed below
-
Authors
Piva, Francesco https://orcid.org/0009-0002-8174-306X
Boccalini, Cecilia https://orcid.org/0000-0002-3518-436X
Ashton, Nicholas J.
Zetterberg, Henrik https://orcid.org/0000-0003-3930-4354
Blennow, Kaj
Frisoni, Giovanni B. https://orcid.org/0000-0002-6419-1753
Veronese, Mattia https://orcid.org/0000-0003-3562-0683
Garibotto, Valentina https://orcid.org/0000-0003-2422-698X
Peretti, Débora Elisa https://orcid.org/0000-0002-3033-8817
-
Funding
Funding for this research was provided by:
University of Geneva
- License Information
-
More Information
Article History
Received: 20 January 2026
Accepted: 4 June 2026
First Online: 15 June 2026
Declarations
:
: The local Ethics Committee (Cantonal Research Ethics Commission, Geneva, Switzerland) approved the study, which have been conducted under the principles of the Declaration of Helsinki and the Internation Conference on Harmonization Good Clinical Practice. All subject provided written informed consent to have collected data be used in research.
: Each patient or their relatives provided signed informed consent for participation in the study and for publication.
: VG received financial support for research and/or speaker fees through her institution from Siemens Healthineers, GE Healthcare, Eli Lilly, Novartis and Roche. G.B.F. has received support, payment, consulting fees or honoraria through his institution for lectures, presentations, speaker bureaus, manuscript writing or educational events from: Biogen, Roche, Diadem, Novo Nordisk, GE Healthcare, OM Pharma and Eisai. H.Z. has served on scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics and Wave; has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly and Roche; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). K.B. has served as a consultant and on advisory boards for Acumen, ALZPath, AriBio, BioArctic, Biogen, Eisai, Lilly, Moleac Pte. Ltd, Novartis, Ono Pharma, Prothena, Roche Diagnostics and Siemens Healthineers; has served on data monitoring committees for Julius Clinical and Novartis; has given lectures, produced educational materials and participated in educational programmes for AC Immune, Biogen, Celdara Medical, Eisai and Roche Diagnostics; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper.Other authors declare that they have no competing interest.
